NCH Healthcare System [ ICU] Antibiogram 2012 (% Susceptible)
organism
55
96
36
80.7
Ps.aeruginosa
41 1
95.1
organism S.aureus
63
36.3
54.5
78.1
87.2 85.1
87.2
87.2
47.2
100
87.2
100
49
94.2
100
78.1
68.5
75
83.3
83.3 88.8
83.3
83.3
86.1
94.1
94.4
88.8
86.1
78
87.5
86.1
80.5
87.8
80.4
78.5
92.8
66.6
92.3
95.2
80.9
#t est
ed
am pic illin cip rof lox aci clin n da my cin da p to my cin ery th r om yci n gen tam gen icin tam icin syn str erg ep tom y y c i lev ns ofl yne oxa rgy cin line zol id mo xifl oxc in nit rof ura nti on oxa cill in rifa mp in tet rac y cl ine tig e cy cli trim ne eth /su lfa van com yci n
K.pneumoniae
1
avg .
E.coli
avg .
#t est
ed am ika cin am pic illin am p/s ulb ce f azo lin ce f ep im e ce f oxi tin ce f taz idim e ce f tria xon e cip rof lox aci n ert ap en em gen tam icin im ipe ne m lev ofl oxa cin nit rof ura nti pip on /ta zo tig e cy clin e tob ram y ci n trim eth /su lfa
data collection period Oct 2010 - Sept 2011
Enterococcus spp. 1
<30
1
38 41.2 100 23.8 95.2 95.2 83.3 61 100 17.6 95.4
38 100 49.2 49.2 36.5 65 65.5 91 95
96.8 100 100 100 14 100
100 90
results should be interpreted with caution since the number of isolates does not meet the statistically valid number of >50 isolates, recommended by CLSI Enterococcus spp. includes: E. faecium, E.faecalis and two VRE's Vancomycin Resistant Enterococci
2
Note to Physician / Pharmacist: For atypical susceptibility patterns or multiply resistant organisms, additional susceptibilities may be available. Please call the Microbiology Dept at 239-436-6591.
NCH Healthcare System ED Antibiogram 2012 Common Gram-Positive Bacterial Pathogens (% - Susceptible) Data Collected Oct 2010 – Sept 2011
Pathogens
Enterococcus spp Staph aureus Strep pneumoniae
Avg. # Test ed
136 55 * 29
A m p i c i l l i n
C e f t r i a x o n e
99 99
C l i n d a m y c i n
70
C i p r o f l o x a c I n
80 64
D a p t o m y c i n
100
E r y t h r o m y c i n
57 59
G e n t a m i c i n
100
G e n t a m i c i n
83
S y n e r g y
L e v o f l o x a c i n
L i n e z o l i d
82 64 100
100 100
N i t r o f u r a n t o i n
99 95
O x a c i l l i n
64
P e n i c i l l i n
68
R i f a m p i n
97
T e t r a c y c l i n e
18 88 76
T i g e c y c l i n e
100 100
T r i m e t h / S u l f a
100
V a n c o m y c i n
100 100 100
Antibiotics which are not reported are either inactive against the organism, or the resistance rate is > 50%, or not a drug of choice. should be viewed with caution since the number of isolates does not meet the statistically valid number of > 50 isolates recommended by the CLSI. • Gentamicin may provide synergistic activity when used in combination therapy with a penicillin (ampicillin) or vancomycin for deep-seeded enterococcal infections. • Rifampin should not be used as a single agent for treatment but may be effectively used as combination therapy with vancomycin, trimethoprim/sulfamethoxazole, or doxycycline or minocycle • Strep pneumoniae: Includes Data from ED patients and Inpatient sterile sites (Blood, CSF, Fluid, Lung Tissue)
# Results
Note to Physician / Pharmacist: For atypical susceptibility patterns or multiply resistant organisms, additional susceptibilities may be available. Please call the Microbiology Dept at 239-436-6591.
NCH Healthcare System ED Urine Antibiogram 2012 Common Gram-Negative Bacterial Pathogens (% - Susceptible) Data Collected Oct 2010 – Sept 2011
Pathogens
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli ESBL Escherichia coli Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens Stenotrophomo nas maltophilia
Avg. # Tested
A m i k a c i n
A m p / S u l b a c t a m
A m p i c i l l i n
C e f a z o l i n
C e f e p i m e
C e f o x i t i n
C e f t r i a x o n e
C i p r o f l o x a c i n
E r t a p e n e m
G e n t a m i c i n
I m i p e n e m
L e v o f l o x a c i n
100
100
100
100
100
100
100
N i t r o f u r a n t o i n
P i p / T a z o b a c t a m
T o b r a m y c i n
T r i m e t h / S u l f a
100
100
100
86
*21
100
100
*29
100
100
96
96
90
100
100
100
90
14
96
100
100
* 17
100
100
76
76
100
100
100
100
100
33
93
100
88
1506
100
95
95
81
100
92
100
81
95
95
91
73
67
100
12
100
73
100
12
92
50
53
59
245
100
93
100
97
99
98
90
145
100
92
92
98
97
96
59
98
88
100
100
* 23
68
53
87
96
0
C e f t a z i d i m e
93
13
76
96
98
98
98
98
97
100
99
94
100
99
100
100
92
100
94
95 23
100
77 96
91
100
26
82
93
71
96
97
100
100
91
91
100
* 30
100 90
■ Antibiotics which are not reported are either inactive against the organism, or , the resistance rate is > 50%, or, not a drug of choice. * Results should be viewed with caution since the number of isolates does not meet the statistically valid number of > 50 isolates recommended by the CLSI.
Note to Physician / Pharmacist: For atypical susceptibility patterns or multiply resistant organisms, additional susceptibilities may be available. Please call the Microbiology Dept at 239-436-6591.
NCH Healthcare System Inpatient Antibiogram 2012 Common Gram-Negative Bacterial Pathogens (% - Susceptible) Inpatient Data Collected Oct 2010 – Sept 2011
Pathogens
Avg. # Tested
A m i k a c i n
A m p / S u l b a c t a m
A m p i c i l l i n
C e f a z o l i n
C e f e p i m e
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli
33
100
100
47
100
74
98
1415
100
ESBL Escherichia coli Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens Stenotrophomo nas maltophilia
138
97
433
99
83
204
99
93
363
97
85
* 23
100
100
60
47
82
C e f o x i t i n
C e f t r i a x o n e
E r t a p e n e m
G e n t a m i c i n
I m i p e n e m
L e v o f l o x a c i n
N i t r o f u r a n t o i n
P i p / T a z o b a c t a m
T o b r a m y c i n
T r i m e t h / S u l f a
85
79
100
89
100
79
87
86
94
79
100
91
91
96
100
98
100
94
7
84
100
98
97
81
82
85
98
89
100
85
33
80
90
88
89
90
64
100
89
100
64
94
94
86
71
3
100
73
100
3
89
77
43
54
99
93
96
96
91
77
98
95
78
88
4
74
C i p r o f l o x a c i n
82
90
0
C e f t a z i d i m e
91
93
93
93
93
92
100
98
89
95
94
95
95
76
100
93
93 23
100
77 96
91
100
87
93
71
89
97
100
100
91
91
100
* 30
100 90
■ Antibiotics which are not reported are either inactive against the organism, or , the resistance rate is > 50%, or, not a drug of choice. * Results should be viewed with caution since the number of isolates does not meet the statistically valid number of > 50 isolates recommended by the CLSI.
Note to Physician / Pharmacist: For atypical susceptibility patterns or multiply resistant organisms, additional susceptibilities may be available. Please call the Microbiology Dept at 239-436-6591.
NCH Healthcare System Inpatient Antibiogram 2012 Common Gram-Positive Bacterial Pathogens (% - Susceptible) Inpatient Data Collected Oct 2010 – Sept 2011
Pathogens
Enterococcus faecium Enterococcus spp Staph aureus Staph epidermidis Strep pneumoniae
Avg. # Test ed
41 230 688 159 * 29
A m p i c i l l i n
C e f t r i a x o n e
96 99
C l i n d a m y c i n
56 55
C i p r o f l o x a c I n
79 45 30
D a p t o m y c i n
100 100
E r y t h r o m y c i n
58 32 59
G e n t a m i c i n
G e n t a m i c i n S y n e r g y
83 69
100 76
L e v o f l o x a c i n
L i n e z o l i d
10 72 45 30 100
100 99 100 100
N i t r o f u r a n t o i n
94 99 99
O x a c i l l i n
45 26
P e n i c i l l i n
68
R i f a m p i n
97 95
T e t r a c y c l i n e
24 17 94 84 76
T i g e c y c l i n e
100 100 100 100
T r i m e t h / S u l f a
98
V a n c o m y c i n
17 100 100 100 100
Antibiotics which are not reported are either inactive against the organism, or the resistance rate is > 50%, or not a drug of choice. # Results should be viewed with caution since the number of isolates does not meet the statistically valid number of > 50 isolates recommended by the CLSI. • Gentamicin may provide synergistic activity when used in combination therapy with a penicillin (ampicillin) or vancomycin for deep-seeded enterococcal infections. • Rifampin should not be used as a single agent for treatment but may be effectively used as combination therapy with vancomycin, trimethoprim/sulfamethoxazole, or doxycycline or minocycle • Strep pneumoniae: Includes Data from ED patients and Inpatient sterile sites (Blood, CSF, Fluid, Lung Tissue)
Note to Physician / Pharmacist: For atypical susceptibility patterns or multiply resistant organisms, additional susceptibilities may be available. Please call the Microbiology Dept at 239-436-6591.
